Pipeline Market Review on Therapeutic Landscape of Rubella (German measles) H2 2016

Albany, New York, November 25, 2016: A latest pipeline guide of pharmaceutical and healthcare disease by Global Market Direct has been launched and added to Market Research Hub’s vast partfolio of research reports. The report is titled as “Rubella (German Measles) - Pipeline Review, H2 2016”. This guide evaluates Rubella’s therapeutics development based on mechanism of action (MoA), drug target, monotherapy products, combination products, route of administration (RoA) and molecule type.

Request for Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=873444

The report offers a brief overview about German measles disease and its therapeutic development. It is an infectious disease caused by a virus called “Rubella”. This directly infects the skin and lymph nodes. The main symptom is a pink spotty rash that starts from the face and spreads to the arms & chest. Other symptoms include mild fever, headaches, swollen glands, joint pain and red eyes. German measles is highly infectious to child bearing women during the first trimester of pregnancy. This disease can even cause miscarriage or birth defects. It is generally transmitted by airborne droplets when an infected person coughs or sneezes.

The report further highlights greater focus on effective drug treatment of Rubella. In addition, increasing R&D programs for development of new therapies to successfully treat the disease is expected to favor the market in the near future. According to the study, German measles is extremely rare in the United States. Most of the cases occur in people who live in countries that don’t offer routine immunization against Rubella. Generally, mainstream medicine doesn't have a specific treatment for German measles as it goes away within a week and the mild symptoms can be managed with bed rest and medicines. But the doctors advise pregnant women for virus vaccine immunization to avoid acquiring German measles. A vaccine named measles-mumps-rubella (MMR) can be used to effectively prevent it. The rubella vaccine was introduced in the late 1960s and due to this vaccine the incidence of German measles has significantly declined. Also, a mixture of proteins in the blood called “Gamma globulin” is offered to prevent the disease.

The Rubella pipeline guide also review the key players involved in therapeutic development for this infection and also features dormant and discontinued projects. Some of the key players are-

• Beijing Minhai Biotechnology Co.
• Biological E. Limited
• Beijing Tiantan Biological Products
• GlaxoSmithKline Plc
• Daiichi Sankyo Company
• Indian Immunologicals Limited
• Prometheon Pharma
• Sinovac Biotech Ltd.
• Zydus Cadila Healthcare Limited

Browse Full Report with TOC: http://www.marketresearchhub.com/report/rubella-german-measles-pipeline-review-h2-2016-report.html

The guide also helps in identifying emerging players in the market along with their portfolios which enhances decision making capabilities for the new entrants.

About Us

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com

This release was published on openPR.